Literature DB >> 16150098

Necrotizing fasciitis during de novo minimal change nephrotic syndrome in a kidney transplant recipient.

V Audard1, A Pardon, O Claude, M Jablonski, P Remy, D Desvaux, L Lantieri, P Lang, P Grimbert.   

Abstract

Skin infections and particularly necrotizing fasciitis (NF) represent a rare but serious complication after transplantation. Optimal management depends on prompt diagnosis with identification of the causative organisms to allow appropriate antibiotic therapy in association with surgical debridement. We report a case of a methicillin-resistant Staphylococcus aureus (MRSA) NF as the single pathogen in a renal transplant recipient, during the course of a de novo minimal-change nephrotic syndrome, treated with high-dose steroids. Antibiotic therapy together with surgical debridement and discontinuation of immunosuppressive treatment led to a complete recovery, despite persistence of the nephrotic syndrome. The development of de novo minimal-change nephrotic syndrome after renal allograft transplantation should alert physicians to the possibility of MRSA NF during an increase in the immunosuppressive regimen.

Entities:  

Mesh:

Year:  2005        PMID: 16150098     DOI: 10.1111/j.1399-3062.2005.00097.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  2 in total

1.  Invasive infections with community-associated methicillin-resistant Staphylococcus aureus after kidney transplantation.

Authors:  Oluwadamilola A Adeyemi; Chao Qi; Teresa R Zembower; Michael G Ison; Thomas H Grant; Brian J Hartigan; Michael Malczynski; Valentina Stosor
Journal:  J Clin Microbiol       Date:  2008-06-04       Impact factor: 5.948

2.  A retrospective study of 22 patients with necrotising fasciitis treated at the University Clinical Center of Kosovo (2005-2010).

Authors:  Hysni M Arifi; Shkelzen B Duci; Violeta K Zatriqi; Hasan R Ahmeti; Vildane H Ismajli; Musli M Gashi; Ylber M Zejnullahu; Agon Y Mekaj
Journal:  Int Wound J       Date:  2012-07-03       Impact factor: 3.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.